Mangement
A 63-year-old retired Professor of Medicine presented with a recurrent, localized marginal zone lymphoma of MALT type involving the lateral canthal/lateral rectus region of the right eye**. This is an unusual but important reminder that persistent or recurrent periocular redness, swelling, or a localized mass should not always be assumed to represent a benign inflammatory condition.
Ocular adnexal lymphoma is uncommon, but among primary ocular adnexal lymphomas, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is the most frequent subtype. It is generally an indolent lymphoma, but it can recur locally or, over time, develop disease at distant or contralateral sites.
In this patient, the lesion had already been treated previously but subsequently **recurred locally**, raising an important management question: what is the best way to obtain durable local control while minimizing radiation-related damage to the eye and surrounding structures?
Why Radiotherapy Is an Important Consideration
For localized ocular adnexal MALT lymphoma, radiotherapy has traditionally been an important definitive treatment because the disease is highly radiosensitive and excellent local control can be achieved. Published series have reported local-control rates approaching 95–100% following radiotherapy in appropriately selected patients.
Modern treatment has increasingly focused on achieving effective tumor control while reducing toxicity. Depending on the exact anatomical extent of the lesion, techniques such as IMRT, VMAT, or carefully planned electron/photon therapy may be considered. Lens shielding or other organ-sparing techniques may be particularly important when the tumor location allows them.
Radiation dose and fractionation should be individualized by an experienced radiation oncologist. Published studies have used a range of regimens. Some series have demonstrated excellent control with approximately **20–25 Gy**, while older data suggested excellent control with approximately **30 Gy**. Therefore, the treatment plan should not simply be based on a fixed dose; it should take into account the previous treatment, recurrence pattern, tumor location, proximity to the globe, lens, optic nerve, lacrimal gland and retina, and the desired normal-tissue constraints.
Radiotherapy is not completely without risk. Depending on the treated volume and dose, patients may develop dry eye, cataract, conjunctival or eyelid changes, and, less commonly, radiation retinopathy or optic neuropathy. Lens-sparing techniques can reduce the risk of radiation-induced cataract when anatomically feasible.
In this particular patient, **PET-CT and MRI have shown no evidence of systemic involvement**, supporting the current impression of a localized recurrence. Nevertheless, because this is a recurrent lymphoma, multidisciplinary review remains important. The pathology should also be reviewed and correlated with the current imaging before definitive treatment.
The Importance of Choosing the Right Radiotherapist
The most important practical question in this case is not simply whether radiotherapy can treat the lymphoma—it can—but **who should plan and deliver it**.
Ocular adnexal radiotherapy requires a balance between adequate treatment of the entire involved tissue and protection of critical ocular structures. A radiation oncologist experienced specifically in **orbital, ocular adnexal, and head-and-neck malignancies** can assess the previous radiation fields, current MRI findings and exact anatomical extent before designing an appropriate plan.
#eye specialist appointment
#OcularLymphoma
#MALTLymphoma
#EyeLymphoma
#OcularAdnexalLymphoma
#OrbitalLymphoma
← Back to all posts